The phase II APPLE trial evaluated two treatment strategies for patients with lung cancer. Results were published by Remon et al in the Journal of Clinical Oncology.
Question 1 of 5
According to results from the phase II EORTC LCG-1613 APPLE trial, osimertinib has been established as a standard-of-care treatment for patients with common sensitizing EGFR-mutant ____.
